AMAG Pharmaceuticals Reports Mixed Q4 Results
Shares of AMAG Pharmaceuticals (NASDAQ: AMAG) are trading unchanged in the after-hours following the release of the company's Q4 earnings results. Currently, shares are bid $15.59, at $17.04; they ended the regular session higher by 0.63%, at $16.09.
AMAG Pharmaceuticals reported Q4 EPS of ($0.87) on revenues of $14.9 million; The Street was looking for ($1.09) per share on revenues of $15.09 million. Revenues decreased 13.4% year over year.
"We are pleased with the progress that we are making in the strategic evaluation of our business and in our efforts to re-establish the growth of Feraheme in 2012," said Frank Thomas, chief operating officer and interim chief executive officer of AMAG.
"As we work to enhance value for our stockholders, we must grow our top line while operating as a leaner, more nimble organization to preserve our financial strength. We believe that the key commercial initiatives being implemented by a new leadership team, coupled with the discipline to manage our business to cash flow breakeven this year, will position us for success on both fronts in 2012."
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.